Transaction in Own Shares
02 November 2026
CVS GROUP plc
("CVS" or the "Company" and, together with its subsidiaries, the "Group")
Transaction in own shares
CVS announces that it purchased the following number of its ordinary shares of 0.2 pence each (“Ordinary Shares”) from Joh. Berenberg, Gossler & Co. KG, London Branch (”Berenberg”), in accordance with the terms of the share buyback programme announced on 26 May 2026 (the "Share Buyback Programme").
|
Date of purchases: |
26/10/2026 – 30/10/2026 |
|
Aggregate number of Ordinary Shares purchased: |
134,615 |
|
Lowest price paid per share (GBp): |
1,289.00 |
|
Highest price paid per share (GBp): |
1,339.00 |
|
Volume weighted average price paid per share (GBp): |
1,317.86 |
CVS intends to cancel all of the purchased Ordinary Shares.
Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 66,695,634 Ordinary Shares in issue and holds no Ordinary Shares in treasury.
The total number of voting rights in CVS is therefore 66,695,634 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.
Since the commencement of the Share Buyback Programme, the Company has repurchased 3,467,465 Ordinary Shares in aggregate at a weighted average price of 1,250.8 pence per share.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, (a full breakdown of the individual trades made by Berenberg as part of the Share Buyback Programme is attached to this announcement).
http://www.rns-pdf.londonstockexchange.com/rns/2723B_1-2026-10-30.pdf
|
Contacts CVS Group plc Richard Fairman, Chief Executive Officer Robin Alfonso, Chief Financial Officer Paul Higgs, Chief Veterinary Officer Charlotte Page, Head of Investor Relations |
via FGS Global |
|
FGS Global Faeth Birch Charlie Chichester |
+44 (0)207 251 3801
|
About CVS Group plc (www.cvsukltd.co.uk)
CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.
The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").
The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE